NTRA - Natera, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
9.06
-0.20 (-2.16%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.26
Open9.18
Bid7.79 x 100
Ask10.08 x 100
Day's Range8.97 - 9.57
52 Week Range7.35 - 14.76
Volume106,108
Avg. Volume115,145
Market Cap487.147M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.43
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire22 days ago

    Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting

    SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama® non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161). Panorama® is the first NIPT that can screen twin pregnancies for zygosity (identical or non-identical twins) and determine gender for each twin as early as 9 weeks' gestation. It is the only NIPT that differentiates between maternal and fetal DNA, which enables women to learn more about their pregnancies through a simple blood draw from the mother, posing no risk to the babies.

  • PR Newswirelast month

    Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018

    SAN CARLOS, Calif., Jan. 8, 2018 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will webcast a live presentation at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, Jan. 11, 2018 at 9:00 a.m. Pacific Time. Natera CEO Matthew Rabinowitz will provide an overview of the company and its latest developments, followed by a question and answer session. COO Steve Chapman and CFO Mike Brophy will be available to answer questions.

  • GlobeNewswirelast month

    New Research Coverage Highlights ConnectOne, Rockwell Medical, Accelerate Diagnostics, Eleven Biotherapeutics, Renasant, and Natera — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Jan. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConnectOne ...

  • Capital Cube3 months ago

    ETFs with exposure to Natera, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Natera, Inc. Here are 5 ETFs with the largest exposure to NTRA-US. Comparing the performance and risk of Natera, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NTRA earnings conference call or presentation 8-Nov-17 9:30pm GMT

    Q3 2017 Natera Inc Earnings Call

  • Associated Press3 months ago

    Natera reports 3Q loss

    The San Carlos, California-based company said it had a loss of 51 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire3 months ago

    Natera Reports Third Quarter 2017 Financial Results

    SAN CARLOS, Calif. , Nov. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results ...

  • ACCESSWIRE3 months ago

    Natera, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Natera, Inc. (NASDAQ: NTRA ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern Time. To ...

  • PR Newswire4 months ago

    Natera Selected for Circulating Tumor DNA Study in Colorectal Cancer

    Second Study with Denmark's Aarhus University to Leverage Signatera™ (RUO) Personalized ctDNA Technology SAN CARLOS, Calif. , Nov. 6, 2017 /PRNewswire/ -- Natera, Inc. , (NASDAQ: NTRA), a global leader ...

  • PR Newswire4 months ago

    Natera Inc. Announces Third Quarter 2017 Earnings Conference Call

    SAN CARLOS, Calif. , Nov. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its third quarter ended September 30, ...

  • PR Newswire4 months ago

    Natera Chosen for Longitudinal Circulating Tumor DNA Study in Breast Cancer

    SAN CARLOS, Calif., Nov. 1, 2017 /PRNewswire/ -- Natera, Inc., (NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Imperial College London and the University of Leicester, U.K., to leverage the company's Signatera™ (RUO) personalized circulating tumor DNA (ctDNA) technology to evaluate retrospectively the use of ctDNA to detect disease recurrence in women breast cancer patients. Signatera™ (RUO) was recently launched for use by oncology researchers and biopharmaceutical companies, and is expected to be available for clinical use next year.

  • Capital Cube4 months ago

    ETFs with exposure to Natera, Inc. : October 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Natera, Inc. Here are 5 ETFs with the largest exposure to NTRA-US. Comparing the performance and risk of Natera, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Natera, Inc. :NTRA-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
    Capital Cube5 months ago

    Natera, Inc. :NTRA-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Natera, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 53.62 million, Net Earnings of USD -27.73 million. Gross margins narrowed from 40.42% to 35.54% compared to the same period last year, operating (EBITDA) margins now -46.95% from -40.94%. Change in operating cash ... Read more (Read more...)

  • PR Newswire5 months ago

    Natera's Panorama Non-Invasive Prenatal Test Now Available for Screening Twin Pregnancies

    SAN CARLOS, Calif., Oct. 2, 2017 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that the company's Panorama® non-invasive prenatal test (NIPT) is now validated to screen twin pregnancies for zygosity (identical or non-identical/fraternal) and chromosomal abnormalities. Panorama identified monozygotic twins with 99% sensitivity and specifi­city in validation studies.1 Monozygotic pregnancies can be at risk for complications that come from monochorionicity (a shared placenta).

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of NTRA earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Natera Inc Earnings Call

  • PR Newswire5 months ago

    Natera Selected for Circulating Tumor DNA Study in Bladder Cancer

    SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™ (RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer. Signatera™ was recently launched for research use only (RUO) for oncology researchers and biopharmaceutical companies, and is not for use in diagnostic procedures.

  • PR Newswire6 months ago

    Natera Launches Signatera™ Personalized Circulating Tumor DNA Technology for Cancer Research

    SAN CARLOS, Calif., Aug. 21, 2017 /PRNewswire/ -- Natera, Inc. (NTRA), a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual's tumor, for research use only (RUO) by oncology researchers and biopharmaceutical companies. Already in clinical validation with multiple world-leading cancer institutes, SignateraTM offers a novel personalized approach to cancer detection in plasma. The technology analyzes whole-exome sequencing data from a patient's tumor sample in order to custom design individual-specific assays, targeting 16 or more mutations known to be present in the tumor tissue ("tumor signatures").

  • Capital Cube6 months ago

    ETFs with exposure to Natera, Inc. : August 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Natera, Inc. Here are 5 ETFs with the largest exposure to NTRA-US. Comparing the performance and risk of Natera, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Associated Press6 months ago

    Natera reports 2Q loss

    On a per-share basis, the San Carlos, California-based company said it had a loss of 52 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire6 months ago

    Natera Reports Second Quarter 2017 Financial Results

    SAN CARLOS, Calif. , Aug. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results ...